Related Experiment Video
Updated: Jul 14, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Intensive Lipid-Lowering Therapy as per the Latest Dyslipidemia Management Guideline in Predicting Favorable
Liang Tang1, Hao Chen1, Xin-Qun Hu1
1Department of Cardiology The Second Xiangya Hospital of Central South University Changsha Hunan China.
Insights
Most patients undergoing coronary artery bypass grafting (CABG) do not achieve their low-density lipoprotein cholesterol (LDL-C) goals one year post-surgery. Poor LDL-C control after CABG is linked to higher risks of major adverse cardiovascular and cerebrovascular events (MACCEs).
Area of Science:
- Cardiology
- Vascular Surgery
- Lipid Metabolism
Background:
- Limited data exist on low-density lipoprotein cholesterol (LDL-C) goal achievement post-coronary artery bypass grafting (CABG) according to 2019 ESC/EAS guidelines.
- The impact of LDL-C levels on long-term outcomes in CABG patients remains under-investigated.
Purpose of the Study:
- To investigate the association between LDL-C levels one year after CABG and long-term patient outcomes.
- To assess the rate of LDL-C goal attainment in patients post-CABG.
Main Methods:
- Retrospective analysis of 2072 patients with multivessel coronary artery disease undergoing CABG (2011-2020).
- Patients categorized by LDL-C levels at 1-year post-CABG.
- Evaluation of major adverse cardiovascular and cerebrovascular events (MACCEs) during a mean 4.2-year follow-up.
Main Results:
- Only 14.9% of patients achieved the LDL-C goal (<1.40 mmol/L) at 1 year post-CABG.
- 25.0% of patients experienced MACCEs during follow-up.
- Higher LDL-C levels (≥2.60 mmol/L) were independently associated with significantly increased risks of MACCEs, cardiac death, myocardial infarction, and revascularization compared to LDL-C <1.40 mmol/L.
Conclusions:
- The majority of patients do not achieve lipid goals one year after CABG.
- Suboptimal LDL-C levels post-CABG are independently associated with increased long-term MACCE risk.
- Prospective studies are needed to confirm if intensive lipid management improves outcomes in CABG patients.
Abstract:
Background There are limited data on low-density lipoprotein cholesterol (LDL-C) goal achievement per the 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia management guidelines and its impact on long-term outcomes in patients undergoing coronary artery bypass grafting (CABG). We investigated the association between LDL-C levels attained 1 year after CABG and the long-term outcomes. Methods and Results A total of 2072 patients diagnosed with multivessel coronary artery disease and undergoing CABG between 2011 and 2020 were included. Patients were categorized by lipid levels at 1 year after CABG, and the occurrence of major adverse cardiovascular and cerebrovascular events (MACCEs) was evaluated. The goal of LDL-C <1.40 mmol/L was attained in only 310 patients (14.9%). During a mean follow-up of 4.2 years after the index 1-year assessment, 25.0% of the patients experienced MACCEs. Multivariable-adjusted hazard ratios (95% CIs) for MACCEs, cardiac death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and cardiac rehospitalization were 1.94 (1.41-2.67), 2.27 (1.29-3.99), 2.45 (1.55-3.88), 1.17 (0.63-2.21), 2.47 (1.31-4.66), and 1.87 (1.19-2.95), respectively, in patients with LDL-C ≥2.60 mmol/L, compared with patients with LDL-C <1.40 mmol/L. The LDL-C levels at 1-year post-CABG were independently associated with long-term MACCEs. Conclusions This retrospective analysis demonstrates that lipid goals are not attained in the vast majority of patients at 1 year after CABG, which is independently associated with the increased risk of long-term MACCEs. Further prospective, multicenter studies are warranted to validate if intensive lipid management could improve the outcomes of patients undergoing CABG.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management

